C4X Discovery - A More Refined Approach
Edison | Mar 29, 2016 06:17AM ET
A more refined approach
C4X's (LON:C4XD) interims revealed a refinement of its hybrid business model, whereby it will stop offering access to its drug discovery technology on a fee-for-service basis, instead seeking to strike more strategic and collaborative agreements with pharma/biotech partners. The recent £1.67m acquisition of Adorial, with an innovative technology to help identify novel drug targets, could significantly enhance and accelerate C4X’s drug discovery capabilities. With £5m in cash as of 31 January 2016, and operating costs on the rise to support pipeline and technology development, we anticipate a fresh financing in H216.
Therapeutic programmes progress
C4X has made progress across a number of therapeutic areas with six pre-clinical projects underway. A number of new drug candidates have been identified across addiction, inflammation and diabetes, with the lead programme, Orexin-1 (for the treatment of addictive disorders) continuing to make good progress with a preclinical candidate and a second differentiated follow-up molecule identified. We anticipate clinical studies to start in mid-2017.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.